Arura Pharma Inc. appoints a new Chief Financial Officer



    MONTREAL, Jan. 28 /CNW Telbec/ - Arura Pharma Inc. (TSXV: ARP) ("Arura")
is pleased to announce that it has appointed Mr. Jean-Marie Pomerleau,
Chartered Accountant, as Chief Financial Officer.
    Mr. Daniel Pharand, Chairman of Arura, stated that "Arura is particularly
pleased to have been able to recruit as Chief Financial Officer a Chartered
Accountant with the pedigree of Mr. Pomerleau, who is retiring from a partner
position with one of the biggest independent accounting firms in Québec to
join Arura to which he brings more than 40 years of experience as advisor to
private and publicly-traded corporations, including in the fields of business
valuation, financing, mergers and acquisitions, tax and audit."

    
    Mr. Pomerleau's career highlights include:

    - Chartered Accountant since 1972;

    - Partner with established accounting firms, including his last
      partnership at Demers Beaulne, a Montréal-based accounting firm
      regrouping more than 100 professionals that he joined in 1997;

    - Chairman of the Board of Reso Investments Inc., a venture capital
      corporation dedicated to the south west of Montreal and of SPINC, an
      organization that seed financed new ventures in the field of digital
      technology for the web and movie industries; and

    - Served as member of the Board of LAB International Inc.
      (now Akela Pharma Inc.: TSX: AKL and LAB Research Inc.: TSX: LRI).
    

    Arura granted to Mr. Pomerleau the option to purchase up to
1,000,000 common shares of Arura at a price of $0.125 per share for a period
of five (5) years from the date of grant. These options are vesting over a
36 months period providing Mr. Pomerleau is still an employee of Arura during
that period and are granted pursuant to Arura's incentive stock option plan.
The option grant is subject to regulatory approval and approval of the
shareholders of Arura fixing the number of shares subject to the plan. The
options and any securities issued upon the exercise of the options are subject
to a four-month hold period.
    Mrs Chantal Boutin, who served as the Chief Financial Officer of Arura on
an interim basis prior to the nomination of Mr. Pomerleau, will continue as
director of finance and administration with the Corporation.

    About Arura Pharma Inc.

    Arura is a specialty pharmaceutical company consisting of two business
units, namely an established consumer health business unit manufacturing and
distributing beauty and personal hygiene products in Canada and in the United
States and an emerging specialty pharmaceutical business unit geared at
acquiring and commercializing established prescription drugs and medical
devices in the oncology, wound care and neurology sectors, amongst others.

    Other Information

    The Exchange has not reviewed and does not accept responsibility for the
    adequacy or accuracy of this press release.

    Cautionary Statement on Forward-Looking Information:

    This release contains certain "forward-looking statements" including,
without limitation, expectations, beliefs, plans and objectives regarding the
potential transactions and ventures discussed in this release. Among the
important factors that could cause actual results to differ materially from
those indicated by such forward-looking statements are the risks inherent in
pharmaceutical manufacturing and distribution, the need to obtain additional
financing, the availability of needed personnel and fluctuations in general
economic conditions.
    %SEDAR: 00025654EF




For further information:

For further information: Daniel Pharand, Chairman, Arura Pharma Inc.,
(514) 984-4431, dpharand@pharcan.com; Ali Moghaddam, Chief Executive Officer,
Arura Pharma Inc., (450) 442-2545 ext. 233, amoghaddam@arurapharma.com

Organization Profile

ARURA PHARMA INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890